• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

30
15
1
1
1

COUNTRY

6
6
1
1
1

CATEGORIES

  • 123
  • 30
  • 29
  • 11
  • 10
  • 9
  • 7
  • 7
  • 5
  • 5
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

110
125
156
249

PUBLISHED

10
27
68
249

PRODUCT TYPE

217
31
1

Search "Dong-A Pharmaceutical Company Limited" returned 249 results.

PRODUCT TITLE

Dong-A Pharmaceutical Co., Ltd. (000640) - Financial and Strategic SWOT Analysis Review

Summary Dong-A Pharmaceutical Co., Ltd (Dong-A) is a research-based pharmaceutical and healthcare company. It focuses on the research and development in various therapeutic areas, including, metabolic/endocrine...

March 2013
FROM
Research Report on Top 100 Enterprises in Chinese Pharmaceutical Industry, 2009-2010 Research Report on Top 100 Enterprises in Chinese Pharmaceutical Industry, 2009-2010 - Product Thumbnail Image

Research Report on Top 100 Enterprises in Chinese Pharmaceutical Industry, 2009-2010

In 2008, the sales of Chinese pharmaceutical industry amounted to RMB 677 776 billion, rising by over 20% YOY Among the sub-industries, the sales growth rate of the biological product industry was 31...

December 2009
FROM

China Health Food Industry Report, 2013

Health food arose in China in 1980s; after three decades of development, China health food industry has formed with the value of RMB100 billion In 2012, the sales revenue of the health food industry...

May 2013
FROM

China Health Food Industry Report, 2013

Health food arose in China in 1980s; after three decades of development, China health food industry has formed with the value of RMB100 billion In 2012, the sales revenue of the health food industry...

May 2013
FROM
China Dietary Supplement Industry Report, 2011-2012 China Dietary Supplement Industry Report, 2011-2012 - Product Thumbnail Image

China Dietary Supplement Industry Report, 2011-2012

In recent years, the dietary supplement industry has entered a new golden development stage in China, with the market size hitting RMB105 billion in 2011 and presenting a CAGR of 11 4% or so during...

May 2012
FROM
China Dietary Supplement Industry Report, 2011-2012 China Dietary Supplement Industry Report, 2011-2012 - Product Thumbnail Image

China Dietary Supplement Industry Report, 2011-2012

In recent years, the dietary supplement industry has entered a new golden development stage in China, with the market size hitting RMB105 billion in 2011 and presenting a CAGR of 11 4% or so during...

May 2012
FROM

Il Dong Pharmaceutical Company Limited

A textual analysis of the financial results for Il Dong Pharmaceutical Company Limited compared to selected competitors. Also included are quantitative analyses of the company's financial statements,...

June 2014

Kwang Dong Pharmaceutical Company Limited

A textual analysis of the financial results for Kwang Dong Pharmaceutical Company Limited compared to selected competitors. Also included are quantitative analyses of the company's financial statements,...

June 2014
Asia-Pacific Pharmaceutical Market Analysis, 2010-2014 Asia-Pacific Pharmaceutical Market Analysis, 2010-2014 - Product Thumbnail Image

Asia-Pacific Pharmaceutical Market Analysis, 2010-2014

Having displayed quite healthy growth rates in the years 2005-2009 the Asia-Pacific pharmaceuticals market is expected to decelerate significantly in 2010 followed by the slow increase in growth in...

August 2010
FROM
South Korea Pharmaceutical Market Analysis, 2010-2014 South Korea Pharmaceutical Market Analysis, 2010-2014 - Product Thumbnail Image

South Korea Pharmaceutical Market Analysis, 2010-2014

Having displayed fluctuating growth rates in the years 2005-2009 the South Korea pharmaceuticals market is expected to stabilize from 2010, showing slight deceleration in growth over the years up to...

August 2010
FROM

Asthma - Pipeline Review, H2 2013

Asthma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Asthma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

August 2013
FROM

Diabetes - Pipeline Review, H2 2013

Diabetes - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Diabetes - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

September 2013
FROM

Lymphoma - Pipeline Review, H2 2013

Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

August 2013
FROM

Dong-A Socio Holdings Co. Ltd. (000640) - Financial and Strategic SWOT Analysis Review

Dong-A Socio Holdings Co. Ltd. (000640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been...

July 2014
FROM

Neuropathic Pain - Pipeline Review, H2 2013

Neuropathic Pain - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM

Shandong Dong-E E-Jiao Co., Ltd.

A textual analysis of the financial results for Shandong Dong-E E-Jiao Co., Ltd. compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive...

June 2014

Women Infertility – Pipeline Review, H1 2013

Global Markets Direct’s, 'Women Infertility - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline This report provides information on the therapeutic development...

February 2013
FROM

Hemophilia A - Pipeline Review, H2 2013

Hemophilia A - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hemophilia A - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM

Type 2 Diabetes - Pipeline Review, H2 2013

Type 2 Diabetes - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Type 2 Diabetes - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM
Competitor Analysis: Erythropoietin (EPO) Competitor Analysis: Erythropoietin (EPO) - Product Thumbnail Image

Competitor Analysis: Erythropoietin (EPO)

The Competitive Intelligence Report Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) as of January 2011 in its 5th edition provides information on existing first and second generation...

January 2011
FROM
Loading Indicator